Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Depreciation & Amortization (CF) (2021 - 2025)

Historic Depreciation & Amortization (CF) for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $1.5 million.

  • Krystal Biotech's Depreciation & Amortization (CF) rose 909.09% to $1.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $5.6 million, marking a year-over-year decrease of 489.53%. This contributed to the annual value of $5.7 million for FY2025, which is 460.0% down from last year.
  • According to the latest figures from Q4 2025, Krystal Biotech's Depreciation & Amortization (CF) is $1.5 million, which was up 909.09% from $1.4 million recorded in Q3 2025.
  • Krystal Biotech's Depreciation & Amortization (CF)'s 5-year high stood at $1.8 million during Q2 2024, with a 5-year trough of $536000.0 in Q1 2021.
  • For the 5-year period, Krystal Biotech's Depreciation & Amortization (CF) averaged around $1.1 million, with its median value being $1.1 million (2022).
  • Per our database at Business Quant, Krystal Biotech's Depreciation & Amortization (CF) plummeted by 3054.19% in 2023 and then skyrocketed by 10241.13% in 2024.
  • Quarter analysis of 5 years shows Krystal Biotech's Depreciation & Amortization (CF) stood at $784000.0 in 2021, then skyrocketed by 38.9% to $1.1 million in 2022, then surged by 38.38% to $1.5 million in 2023, then decreased by 7.3% to $1.4 million in 2024, then rose by 9.09% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q4 2025, $1.4 million for Q3 2025, and $1.3 million during Q2 2025.